Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (101-110 of 289) with videos related to

Pageof 29
Sort By:
Clinical Drug Investigation|January 8, 2021
Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical TrialsSawsan Rashdan, Hui Yang, Tri Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 22, 2010
Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapyDavid E Gerber, Drew W Rasco, Phat Le, et al.
JCO Oncology Practice|August 11, 2021
Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 PandemicErin L Williams, Desiree L Pierre, Mary E Martin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2016
Axl Receptor Axis: A New Therapeutic Target in Lung CancerPavel A Levin, Rolf A Brekken, Lauren Averett Byers, et al.
Patient Education and Counseling|May 29, 2012
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancerDavid E Gerber, Heidi A Hamann, Drew W Rasco, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical TrialsMatthew Perez, Caitlin C Murphy, Sandi L Pruitt, et al.
Clinical Lung Cancer|July 27, 2013
Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancerDaniel H Ahn, Nishi Mehta, Jeffrey T Yorio, et al.
JTO Clinical and Research Reports|July 25, 2022
Distinct NSCLC <i>EGFR</i> Variants in a Family With Li-Fraumeni Syndrome: Case ReportShelby Edmondson, Mitchell S von Itzstein, Brian Reys, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2015
Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR InhibitionPavel A Levin, Melissa Mayer, Sharon Hoskin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2018
Development and Validation of a Nomogram Prognostic Model for SCLC PatientsShidan Wang, Lin Yang, Bo Ci, et al.
Pageof 29

Showing results (101-110 of 289) with videos related to

Sort By:
Pageof 29
Clinical Drug Investigation|January 8, 2021
Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical TrialsSawsan Rashdan, Hui Yang, Tri Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 22, 2010
Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapyDavid E Gerber, Drew W Rasco, Phat Le, et al.
JCO Oncology Practice|August 11, 2021
Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 PandemicErin L Williams, Desiree L Pierre, Mary E Martin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2016
Axl Receptor Axis: A New Therapeutic Target in Lung CancerPavel A Levin, Rolf A Brekken, Lauren Averett Byers, et al.
Patient Education and Counseling|May 29, 2012
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancerDavid E Gerber, Heidi A Hamann, Drew W Rasco, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical TrialsMatthew Perez, Caitlin C Murphy, Sandi L Pruitt, et al.
Clinical Lung Cancer|July 27, 2013
Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancerDaniel H Ahn, Nishi Mehta, Jeffrey T Yorio, et al.
JTO Clinical and Research Reports|July 25, 2022
Distinct NSCLC <i>EGFR</i> Variants in a Family With Li-Fraumeni Syndrome: Case ReportShelby Edmondson, Mitchell S von Itzstein, Brian Reys, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2015
Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR InhibitionPavel A Levin, Melissa Mayer, Sharon Hoskin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2018
Development and Validation of a Nomogram Prognostic Model for SCLC PatientsShidan Wang, Lin Yang, Bo Ci, et al.
Pageof 29